Last reviewed · How we verify
LBL-015 for Injections
At a glance
| Generic name | LBL-015 for Injections |
|---|---|
| Also known as | LBL-015 |
| Sponsor | Nanjing Leads Biolabs Co.,Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase I/II Clinical Trial of LBL-015 for Injection (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LBL-015 for Injections CI brief — competitive landscape report
- LBL-015 for Injections updates RSS · CI watch RSS
- Nanjing Leads Biolabs Co.,Ltd portfolio CI